Imaging neural correlates of antidepressant action of ketamine stereoisomers using pharmacological PET/MR imaging and metabolite analysis.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519234-23-00

Acronym

RS-Ket_PETMR

Enrollment

Registered

2025-01-30

Start date

2020-01-17

Completion date

Unknown

Last updated

2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers - no medical condition

Brief summary

regional cerebral metabolic rate of glucose (rCMRGlu), cerebral blood flow (CBF), functional connectivity (FC), Volumen (GMV), mean diffusivity (MD), fractional anisotropy (FA)

Detailed description

Psychopathological effects of administration of the study medication

Interventions

DRUGKetamin-hameln 50 mg/ml Injektionslösung

DRUGSaline Solution Basi 9 mg/ml solution for infusion

DRUGKetanest® S 25 mg/ml - Ampullen

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
regional cerebral metabolic rate of glucose (rCMRGlu), cerebral blood flow (CBF), functional connectivity (FC), Volumen (GMV), mean diffusivity (MD), fractional anisotropy (FA)	—

Secondary

Measure	Time frame
Psychopathological effects of administration of the study medication	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026